Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-11-22

FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for KALETRA (lopinavir/ritonavir) from AbbVie, updating the product labeling as a result of the submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kaletra (lopinavir)

Snippet

SUPPL AP for KALETRA (LOPINAVIR AND RITONAVIR)